That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...